Kintara Therapeutics, Inc. (NASDAQ: KTRA) CEO Saiid Zarrabian talks to Proactive about the San Diego-based biopharmaceutical company's upcoming milestones next year.
Zarrabian says within the next 30-90 days the group is expecting to announce the initiation of its Global Coalition for Adaptive Research GBM AGILE Registrational study. Going forward, Zarrabian adds it expects to publish the top-line results from its current ongoing Phase 2 trials in 1Q and 2Q next year.
Price: 1.71 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Retail & consumer
HempFusion (TSE: CBD- OTCQX: CBDHF) CEO Jason Mitchell joined Steve Darling from Proactive to share news the company has submitted its dossier to the United Kingdom's Regulatory Food Safety Agency. Mitchell telling Proactive the first step in the United Kingdom’s regulatory approval process...
Retail & consumer
FansUnite Entertainment files paperwork for B2B and B2C gambling...
Energy
Gran Tierra Energy 'quite comfortable' in its forecasts to produce...
